Cellectar Biosciences Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of June 30, 2026, Cellectar reported cash and cash equivalents of approximately $34.0 million, up from $13.2 million at the end of 2025, largely due to an oversubscribed financing round completed in May.

Net Loss: The net loss for Q2 2026 was $6.9 million ($0.57 per share), compared to $5.4 million ($3.39 per share) in Q2 2025.

R&D Expenses: Increased to $4.6 million from $2.4 million year-over-year, reflecting heightened clinical study activities.

G&A Expenses: Decreased to $2.6 million from $3.6 million, primarily due to reduced professional fees and personnel costs.

2Strategic Updates and Business Highlights

Clinical Development: Progress on iopofosine I 131 for relapsed or refractory Waldenstrom's macroglobulinemia (WM) includes successful completion of the CLOVER-WaM study, which met all primary and secondary endpoints. Notable results presented at ASCO 2026 showed a 79.2% major response rate and a 100% clinical benefit rate in patients treated post-BTK inhibitor therapy.

Regulatory Path: Initiation of site activation for a confirmatory Phase III study is underway, with plans to submit a new drug application (NDA) under the FDA's accelerated approval program by mid-2027.

Financing: The recent financing provides up to $140 million, enhancing the company’s ability to advance its WM strategy and broader pipeline, including the phospholipid drug conjugate (PDC) platform.

Pipeline Expansion: Continued advancement of CLR 125, an Auger-emitting program for solid tumors, with initial data expected later this year or early next year.

3Forward Guidance and Outlook

Regulatory Submission: The company aims to submit an NDA in mid-2027, contingent on successful site activation and patient enrollment in the Phase III study.

Commercial Readiness: Cellectar is preparing for potential commercial launch post-accelerated approval, with a scalable production capability for iopofosine that could support approximately 100 patients per week.

4Bad News, Challenges, or Points of Concern

Increased Losses: The net loss has increased compared to the previous year, raising concerns about ongoing operational costs as the company scales its clinical trials.

Regulatory Risks: The timeline for FDA submission and approval is contingent on several factors, including patient enrollment and site readiness, which could introduce delays.

Market Competition: While the company notes limited competitive tension in the WM space, the potential for future competition in radiopharmaceuticals remains a concern as more companies enter the field.

5Notable Q&A Insights

Phase III Study Enrollment: Management discussed the complexities of initiating the Phase III study, including site activation, IRB approvals, and the need for a certain number of patients enrolled before FDA submission. They anticipate first patient enrollment could occur late this year or early next year.

CLR 125 Data Timeline: While specific timelines for CLR 125 data updates were not disclosed, management indicated that initial dosimetry and safety data might be presented at the San Antonio Breast Cancer Conference.

Commercial Supply Readiness: The company has established a commercial infrastructure for iopofosine and is prepared to scale production quickly upon receiving FDA approval, although they emphasized the need for strategic investment decisions to optimize launch timing. Overall, Cellectar Biosciences is positioned for significant developments in the coming year, particularly with its lead asset, iopofosine, while navigating the challenges of clinical execution and regulatory approval.